https://sourceglp-1.com/blog/next-gen-glp1-trials.html
Next-Gen GLP-1s: Retatrutide, Amycretin & Orforglipron Trial Data | SourceGLP-1
Retatrutide delivers 28.7% weight loss in Phase 3. Amycretin hits 22%. Orforglipron offers needle-free daily pill. Complete trial data on what's coming next.
next genglpretatrutideamycretinorforglipron
https://nordicstoday.com/article/denmark-novo-nordisk-obesity-drug-eu-approval
New Danish Obesity Drug Amycretin Wins EU Approval This Month |
obesity drugthis monthnewdanishamycretin